These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9020373)

  • 1. 2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders.
    Rondelli D; Lauria F; Zinzani PL; Raspadori D; Ventura MA; Galieni P; Birtolo S; Forconi F; Algeri R; Tura S
    Eur J Haematol; 1997 Jan; 58(1):46-50. PubMed ID: 9020373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies.
    Robak T; Smolewski P; Urbanska-Rys H; Gora-Tybor J; Blonski JZ; Kasznicki M
    Leuk Lymphoma; 2004 May; 45(5):937-44. PubMed ID: 15291352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-Chlorodeoxyadenosine treatment in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia resistant to conventional chemotherapy: results of a multicentric experience. International Society for Chemo-Immunotherapy.
    Brugiatelli M; Holowiecka B; Dmoszynska A; Krieger O; Planinc-Peraica A; Labar B; Callea V; Morabito F; Jaksic B; Holowiecki J; Lutz D
    Ann Hematol; 1996 Aug; 73(2):79-84. PubMed ID: 8774616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cladribine in the treatment of chronic lymphocytic leukemia.
    Robak T
    Leuk Lymphoma; 2001 Feb; 40(5-6):551-64. PubMed ID: 11426528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma.
    Robak T; Smolewski P; Cebula B; Szmigielska-Kaplon A; Chojnowski K; Blonski JZ
    Cancer; 2006 Oct; 107(7):1542-50. PubMed ID: 16948126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias.
    Betticher DC; Fey MF; von Rohr A; Tobler A; Jenzer H; Gratwohl A; Lohri A; Pugin P; Hess U; Pagani O
    Ann Oncol; 1994 Jan; 5(1):57-64. PubMed ID: 7909685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-Chlorodeoxyadenosine (2-CdA) in the treatment of patients with relapsed chronic lymphocytic leukemia.
    Krykowski E; Warzocha K; Robak T
    Arch Immunol Ther Exp (Warsz); 1995; 43(5-6):317-21. PubMed ID: 8744653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia.
    Tallman MS; Hakimian D; Zanzig C; Hogan DK; Rademaker A; Rose E; Variakojis D
    J Clin Oncol; 1995 Apr; 13(4):983-8. PubMed ID: 7707127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-Chlorodeoxyadenosine in cutaneous T-cell lymphoproliferative disorders.
    Kong LR; Samuelson E; Rosen ST; Roenigk HH; Tallman MS; Rademaker AW; Kuzel TM
    Leuk Lymphoma; 1997 Jun; 26(1-2):89-97. PubMed ID: 9250792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma.
    Tulpule A; Schiller G; Harvey-Buchanan LA; Lee M; Espina BM; Khan AU; Boswell W; Nathwani B; Levine AM
    Cancer; 1998 Dec; 83(11):2370-6. PubMed ID: 9840537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia.
    Robak T; Błasinka-Morawiec M; Krykowski E; Kasznicki M; Płuzanska A; Potemski P; Hellmann A; Zaucha JM; Lewandowski K; Dmoszynska A; Hansz J; Komarnicki M; Konopka L; Durzynski T; Ceglarek B; Sikorska A; Kotlarek-Haus S; Mazur G; Urasinski I; Zdziarska B; Maj S; Kopec I; Skotnicki AB; Dwilewicz-Trojaczek J; Grieb P
    Leuk Lymphoma; 1996 Aug; 22(5-6):509-14. PubMed ID: 8882965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma.
    Kong LR; Huang CF; Hakimian D; Variakojis D; Klein L; Kuzel TM; Gordon LI; Zanzig C; Wollins E; Tallman MS
    Cancer; 1998 Mar; 82(5):957-64. PubMed ID: 9486587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia.
    Juliusson G; Liliemark J
    Ann Oncol; 1996 Apr; 7(4):373-9. PubMed ID: 8805929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.
    Robak T; Błasińska-Morawiec M; Błoński J; Hellmann A; Hałaburda K; Konopka L; Kotlarek-Haus S; Potoczek S; Hansz J; Dmoszyńska A; Urasiński I; Zdziarska B; Dwilewicz-Trojaczek J; Hołowiecki J; Skotnicki AB
    Eur J Haematol; 1999 Jan; 62(1):49-56. PubMed ID: 9918312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-Chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia.
    Robak T; Błasińska-Morawiec M; Błoński JZ; Dmoszyńska A
    Leuk Lymphoma; 1999 Jun; 34(1-2):151-7. PubMed ID: 10350343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders.
    Frewin R; Turner D; Tighe M; Davies S; Rule S; Johnson S
    Br J Haematol; 1999 Mar; 104(3):612-3. PubMed ID: 10086802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-Chlorodeoxyadenosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger.
    Robak T; Błoński JZ; Urbańska-Ryś H; Błasińska-Morawiec M; Skotnicki AB
    Leukemia; 1999 Apr; 13(4):518-23. PubMed ID: 10214856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study.
    Tondini C; Balzarotti M; Rampinelli I; Valagussa P; Luoni M; De Paoli A; Santoro A; Bonadonna G
    Ann Oncol; 2000 Feb; 11(2):231-3. PubMed ID: 10761763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Major activity of cladribine in patients with de novo B-cell prolymphocytic leukemia.
    Saven A; Lee T; Schlutz M; Jacobs A; Ellison D; Longmire R; Piro L
    J Clin Oncol; 1997 Jan; 15(1):37-43. PubMed ID: 8996122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
    Nagai H; Ogura M; Kusumoto S; Takahashi N; Yamaguchi M; Takayama N; Kinoshita T; Motoji T; Ohyashiki K; Kosugi H; Matsuda S; Ohnishi K; Omachi K; Hotta T
    Eur J Haematol; 2011 Feb; 86(2):117-23. PubMed ID: 21070370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.